$KZIA News

BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer

Kazia Therapeutics Announces New Preclinical Data Showing Safety, Anti-Tumor Activity Of Paxalisib In HR+/HER2- Breast Cancer; First Patient Expected By Year-End 2026 And Full Enrollment By End Of 2027

Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data

Kazia Therapeutics Announces Pricing Of $40M Underwritten Offering Of ADSs And Pre-Funded Warrants

Kazia Therapeutics Prices ~$40M Offering Of 2.58M American Depositary Shares At $17.825 Per ADS

Kazia Therapeutics Commences Offering Of American Depositary Shares; Terms Undisclosed

Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib

Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

Kazia Therapeutics Files Provisional Patent Application Supporting Therapeutic Strategy Designed To Prevent Metastatic Recurrence In Patients With High-Risk Early-Stage Triple-Negative Breast Cancer

BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34

Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Appoints James Levine As CFO, Effective June 1

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Expands Enrollment In Phase 1b Trial For Breast Cancer Treatment Paxalisib

Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst

How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform